Instrument Inactif

Autres langues Bionomics OTC Markets

Actions

BNOEF

AU000000BNO5

Recherche biotechnologique et médicale

Autres langues

23/07	Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million.
23/07	Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell
23/07	Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq
23/07	Stocks down as eurozone rate call nears
23/07	Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
23/07	Scancell, Neuphoria Therapeutics Agree All-share Merger
29/06	Neuphoria responds to the announcement made by London-listed Scancell Holdings plc
26/06	Neuphoria Confirms Business Combination Talks With Scancell
26/06	Neuphoria Responds to the Announcement Made by London-Listed Scancell Holdings plc
26/06	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
26/06	Scancell Confirms Advanced Talks for Potential Acquisition of Nasdaq-listed Neuphoria Therapeutics
26/06	Scancell confirms advanced talks on takeover of Neuphoria; eyes Nasdaq
26/06	Scancell Confirms Advanced Talks over Reverse Merger with Neuphoria
15/05	Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026
17/02	Neuphoria Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025
08/01	Neuphoria Therapeutics Inc. Announces Termination of Spyridon Papapetropoulos as CEO and Appointment as Interim CEO Effective December 31, 2025
08/01	Neuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026
17/12	Declaration of Voting Results by Neuphoria Therapeutics
17/12	Neuphoria Therapeutics Inc. Approves Appointment of Stephen Doberstein and Kimberly Smith as Class I Directors for A Three-Year Term
08/12	Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees
08/12	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
04/12	Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium
04/12	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
03/12	Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics
02/12	Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement